scholarly journals Successful Pregnancy Outcome in a Patient with Antiphospholipid Syndrome : A Case Report

2013 ◽  
Vol 3 (1) ◽  
pp. 44-46
Author(s):  
Hasna Fahmima Haque ◽  
Muhammad Abdur Rahim ◽  
Mohammad Gaffar Amin ◽  
Shahana Zaman ◽  
Pratik Dewan ◽  
...  
Keyword(s):  
Pregnancy Outcome ◽  
Antiphospholipid Syndrome ◽  
Pregnancy Loss ◽  
Low Dose ◽  
Recurrent Pregnancy Loss ◽  
Fetal Loss ◽  
Successful Pregnancy ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
High Index Of Suspicion

Antiphospholipid syndrome (APS) manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss. Diagnosis requires a high index of suspicion during evaluation of women with recurrent pregnancy loss and vascular thrombosis. Low dose aspirin combined with heparin can reduce morbidity and improve the pregnancy outcome. Here we report a case of a 22 year old lady having APS who presented with arthritis, recurrent miscarriages and venous thrombosis. Birdem Med J 2013; 3(1): 44-46 DOI: http://dx.doi.org/10.3329/birdem.v3i1.17126

scholarly journals The effect of low dose aspirin and low molecular weight heparin (enoxaparin) in recurrent pregnancy loss associated with antiphospholipid antibody syndrome

2017 ◽  
Vol 6 (11) ◽  
pp. 4830 ◽  
Author(s):  
Sasmita Swain ◽  
Sujata Singh
Keyword(s):  
Antiphospholipid Syndrome ◽  
Live Birth ◽  
Antiphospholipid Antibodies ◽  
Pregnancy Loss ◽  
Low Dose ◽  
Recurrent Pregnancy Loss ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Background: Recurrent miscarriage affects 1–2% of women. Recurrent pregnancy loss (RPL) is the loss of three or more consecutive pregnancies before or during the 20th week of gestation. The most important association between gestational loss and autoimmune phenomena is the presence of antiphospholipid antibodies represented by the lupus anticoagulants and or anticardiolipin antibodies (Antiphospholipid Antibody Syndrome). The antiphospholipid syndrome is an acquired autoimmune. The clinical features are thrombosis (venous, arterial and microvascular) and/or pregnancy complications; the most prominent of which is recurrent abortion.Methods: Twenty-two selected patients during pregnancy with clinical and/or serological findings of antiphospholipid syndrome had received low dose aspirin (75 mg once daily orally) plus LMWH enoxaparin (40 mg subcutaneously/day).Results: There are live born in 86% cases compared to abortion (< 20 weeks gestational age) in 14 % cases. From 19 liveborn babies the mother having normotensive in 79% and preeclampsia 21%, 85% babies having normal growth and 15% are IUGR. 36% cases are at term (>37 weeks) and 50% cases are at preterm (<37 week) on which 9%) is spontaneous preterm and 41% is iatrogenic preterm due to preeclampsia, IUGR, PPROM and APH.Conclusions: Use of low dose aspirin (75mg) and enoxaparin 40 mg subcutaneously daily in patients with RPL due to antiphospholipid syndrome resulted in higher live birth rates. Combination treatment with aspirin and LMWH leads to a high live birth rate among women with recurrent abortion and antiphospholipid antibodies. 

scholarly journals Comparative study of low dose aspirin versus combination of low dose aspirin and low molecular weight heparin in idiopathic recurrent pregnancy loss

2020 ◽  
Vol 9 (2) ◽  
pp. 512
Author(s):  
S. Bhanu Rekha ◽  
K. Sharath Chandra
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Pregnancy Loss ◽  
Birth Rate ◽  
Low Dose ◽  
Recurrent Pregnancy Loss ◽  
Live Birth Rate ◽  
Low Molecular Weight ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Background: To compare the role of low dose aspirin versus combination of low dose aspirin and low molecular weight heparin in idiopathic recurrent pregnancy loss and assess the effectiveness of low dose aspirin and low molecular weight heparin in having a better obstetric outcome.Methods: This study was conducted in a private hospital in Mahabubnagar from June 2017 to May 2019. A total of 80 pregnant ladies who had previous 2 and or more pregnancy losses in the early (before 20 weeks) or late (after 20 weeks) pregnancy period was included in the study. 80 pregnant women with idiopathic/unexplained recurrent pregnancy loss were properly evaluated in regard to the history of previous period of gestation of loss, previous scans in regard to documentation of fetal pole and gestation, cardiac activity, anomaly scan and growth scan and any special investigations in previous pregnancies and present pregnancy.Results: A total 80 pregnant women with previous 2 and more unexplained pregnancy losses who were evaluated and found negative with major causes of pregnancy losses half of them (40) were treated with low dose aspirin alone and the other 40 women were treated with a combination of low dose aspirin (75 mg) and low molecular weight Heparin (20 mg) daily low molecular weight heparin till term. The aspirin alone group had 82.5% live birth rate and the combination group had 92.5% live birth rate which is quite satisfactory and more than the Aspirin alone group.Conclusions: Use of combination of low dose aspirin and low molecular weight heparin seems to be a good choice of drugs in treating the unexplained recurrent pregnancy losses than low dose aspirin alone.

scholarly journals Comparison of empirical use of low dose aspirin and enoxaprin in the treatment of unexplained recurrent pregnancy loss

2020 ◽  
Vol 9 (3) ◽  
pp. 1138
Author(s):  
Sunil Kumar Juneja ◽  
Pooja Tandon ◽  
Gagandeep Kaur ◽  
Bakul Kapoor ◽  
Guneet Singh Sidhu
Keyword(s):  
Live Birth ◽  
Pregnancy Loss ◽  
Low Dose ◽  
Recurrent Pregnancy Loss ◽  
Chromosomal Anomalies ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Uterine Anomalies ◽  
Significant Difference ◽  
Recurrent Pregnancy Losses

Background: Recurrent pregnancy losses have commonly been defined as three or more consecutive spontaneous pregnancy losses. About 1-2% of women suffer from recurrent miscarriages. The cause is multifactorial such as uterine anomalies, endocrine disorders, immunological causes, infections, chromosomal anomalies and maternal autoimmune diseases. In 50-60% of cases recurrent pregnancy losses, the cause remains unclear. Objective of this study was to compare the maternal and fetal outcome in patients with unexplained recurrent pregnancy loss treated with LMWH (Enoxaparin) vs Aspirin during pregnancy.Methods: Women with 3 or more pregnancy losses, aged between 18-40 years, booked for antenatal care and delivery in our hospital between January 2012 and December 2016 were followed till 6 months after delivery.Results: A total number of 146 women were assessed for eligibility. We had 62 women in Group A (aspirin group) and 84 women in Group E (enoxaparin group). Enoxaparin was given to all those ladies who had taken aspirin in previous pregnancies with no live outcome. Good neonatal outcome was observed with Enoxaparin.Conclusions: Live birth rates did not show significant difference between the two study groups. But empirical use of enoxaparin in patients with no live birth who have taken low dose aspirin in previous pregnancy had shown improved results, so enoxaparin should be used empirically as a first line agent in such cases.

Gestational Age Above 12 Weeks Predicts Favorable Obstetric Outcome in Women with Antiphospholipid Syndrome (APS) Associated with First-Trimester Recurrent Pregnancy Loss (RPL) Treated with Enoxaparin and Low Dose Aspirin.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4004-4004
Author(s):  
Luis S. Noble ◽  
Juan Herrada ◽  
William H. Kutteh
Keyword(s):  
Pregnant Women ◽  
Pregnancy Loss ◽  
Low Dose ◽  
Recurrent Pregnancy Loss ◽  
First Trimester ◽  
Obstetric Outcome ◽  
Complete Evaluation ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Design And Methods

Abstract Background: Pregnant women with APS associated with RPL treated with enoxaparin and low dose aspirin (ASA) resulted in an 84% viable infant delivery (Fertil Steril. 2005 Mar;83(3):684–90). Design and Methods: Retrospective analysis. 30 patients (pts) were enrolled. Mean chronological age was 33.4 years. All pts had 2 or more first trimester losses and had a complete evaluation for RPL including anatomical, hormonal, infectious, chromosomal, and immunological. A standard ELISA was employed to detect the presence of IgG, IgM, and IgA serum antibodies against the phospholipids cardiolipin, inositol, serine, and ethanolamine. All pts received ASA 81 mg orally and enoxaparin 40 mg subcutaneously daily as soon as the serum pregnancy test became positive. Pts were monitored at monthly intervals. Results: Conclusions: We did not observe miscarriages in pregnant women with APS associated with first trimester RPL treated with enoxaparin and low dose aspirin after the 12th week of pregnancy.

Sign in / Sign up

Export Citation Format

Share Document